See more : Boralex Inc. (BRLXF) Income Statement Analysis – Financial Results
Complete financial analysis of Orchard Therapeutics plc (ORTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Orchard Therapeutics plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Invercap S.A. (INVERCAP.SN) Income Statement Analysis – Financial Results
- GigInternational1, Inc. (GIW) Income Statement Analysis – Financial Results
- Yojee Limited (YOJ.AX) Income Statement Analysis – Financial Results
- Good Works Acquisition Corp. (GWAC) Income Statement Analysis – Financial Results
- Hagag Europe Development Z.F. Ltd (HGGE.TA) Income Statement Analysis – Financial Results
Orchard Therapeutics plc (ORTX)
About Orchard Therapeutics plc
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 6.99M | 483.00K | 2.60M | 2.51M | 2.08M | 0.00 | 0.00 |
| Cost of Revenue | 2.43M | 226.00K | 857.00K | 805.00K | 422.00K | 0.00 | 0.00 |
| Gross Profit | 4.55M | 257.00K | 1.74M | 1.71M | 1.65M | 0.00 | 0.00 |
| Gross Profit Ratio | 65.17% | 53.21% | 66.97% | 67.97% | 79.67% | 0.00% | 0.00% |
| Research & Development | 25.55M | 23.35M | 93.73M | 117.36M | 205.32M | 32.53M | 16.21M |
| General & Administrative | 44.66M | 49.65M | 56.89M | 49.16M | 0.00 | 5.99M | 3.00M |
| Selling & Marketing | 4.14M | 5.26M | 8.09M | 8.06M | 0.00 | 0.00 | 0.00 |
| SG&A | 10.60M | 13.55M | 64.99M | 57.22M | 31.37M | 5.99M | 3.00M |
| Other Expenses | 22.66M | 811.00K | 3.41M | 1.39M | 5.51M | -1.18M | 138.00K |
| Operating Expenses | 36.15M | 36.90M | 158.72M | 174.58M | 236.69M | 38.51M | 19.20M |
| Cost & Expenses | 38.58M | 36.90M | 159.57M | 175.39M | 237.11M | 38.51M | 19.20M |
| Interest Income | 857.00K | 63.00K | 3.19M | 7.36M | 0.00 | 0.00 | 3.00K |
| Interest Expense | 933.00K | 683.00K | 2.33M | 1.54M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 23.51M | 874.00K | 8.60M | 8.75M | 1.20M | 302.00K | 6.00K |
| EBITDA | -8.08M | -35.54M | -148.38M | -164.12M | -235.03M | -38.21M | -19.20M |
| EBITDA Ratio | -115.65% | -7,358.39% | -5,717.84% | -6,531.00% | -11,321.34% | 0.00% | 0.00% |
| Operating Income | -31.59M | -36.42M | -156.98M | -172.87M | -235.03M | -38.51M | -19.20M |
| Operating Income Ratio | -452.22% | -7,539.34% | -6,049.25% | -6,879.15% | -11,321.34% | 0.00% | 0.00% |
| Total Other Income/Expenses | -25.95M | -3.32M | 4.27M | 7.21M | 5.51M | -1.18M | 138.00K |
| Income Before Tax | -9.01M | -36.22M | -152.71M | -165.66M | -229.53M | -39.69M | -19.07M |
| Income Before Tax Ratio | -129.00% | -7,499.79% | -5,884.78% | -6,592.20% | -11,056.12% | 0.00% | 0.00% |
| Income Tax Expense | -1.13M | 125.00K | -731.00K | -2.24M | 970.00K | 53.00K | 20.00K |
| Net Income | -7.88M | -36.35M | -151.98M | -163.42M | -230.50M | -39.74M | -19.09M |
| Net Income Ratio | -112.84% | -7,525.67% | -5,856.61% | -6,503.06% | -11,102.84% | 0.00% | 0.00% |
| EPS | -0.61 | -2.93 | -15.28 | -17.53 | -102.17 | -39.37 | -18.90 |
| EPS Diluted | -0.61 | -2.93 | -15.28 | -17.53 | -102.17 | -39.37 | -18.90 |
| Weighted Avg Shares Out | 12.80M | 12.40M | 9.94M | 9.32M | 2.26M | 1.01M | 1.01M |
| Weighted Avg Shares Out (Dil) | 12.82M | 12.40M | 9.94M | 9.32M | 2.26M | 1.01M | 1.01M |
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln
Kyowa Kirin to Acquire Orchard Therapeutics
Orchard Therapeutics PLC Sponsored ADR (ORTX) Soars 12.9%: Is Further Upside Left in the Stock?
Orchard's (ORTX) Rare Neuro Drug Gets FDA Priority Tag, Stock Up
Orchard Therapeutics: A Reassessment
Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023
Wall Street Analysts Think Orchard Therapeutics PLC Sponsored ADR (ORTX) Could Surge 365.03%: Read This Before Placing a Bet
Orchard Therapeutics plc (ORTX) Q2 2023 Earnings Call Transcript
Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA
Source: https://incomestatements.info
Category: Stock Reports